{"id":55618,"date":"2026-01-27T18:09:29","date_gmt":"2026-01-27T10:09:29","guid":{"rendered":"https:\/\/flcube.com\/?p=55618"},"modified":"2026-01-27T18:09:30","modified_gmt":"2026-01-27T10:09:30","slug":"aucta-pharma-files-for-hong-kong-ipo-with-cns-and-rare-disease-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55618","title":{"rendered":"Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline"},"content":{"rendered":"\n<p><strong>Shanghai Aucta Pharmaceuticals Co., Ltd.<\/strong> made its initial public offering (IPO) filing to the <strong>Hong Kong Stock Exchange<\/strong>, positioning to become the next China\u2011based specialty pharma to tap public markets. Unit pricing and offering details remain undisclosed pending regulatory review.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-filing-amp-company-overview\">IPO Filing &amp; Company Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Aucta Pharmaceuticals Co., Ltd.<\/td><\/tr><tr><td><strong>Filing<\/strong><\/td><td>Hong Kong Stock Exchange IPO application<\/td><\/tr><tr><td><strong>Business Model<\/strong><\/td><td>Research\u2011driven specialty pharma (R&amp;D, manufacturing, commercialization)<\/td><\/tr><tr><td><strong>Strategic Focus<\/strong><\/td><td>Central nervous system (CNS) diseases, metabolic diseases, rare diseases<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>In\u2011house innovative drug delivery platform<\/td><\/tr><tr><td><strong>Integration<\/strong><\/td><td>End\u2011to\u2011end system covering R&amp;D, production, sales, and marketing<\/td><\/tr><tr><td><strong>Ticker<\/strong><\/td><td>To be assigned<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-pipeline-amp-product-portfolio\">Core Pipeline &amp; Product Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Indication<\/th><th>Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>AUC033<\/strong><\/td><td>Epilepsy<\/td><td>Core product<\/td><\/tr><tr><td><strong>AUC051<\/strong><\/td><td>Epilepsy<\/td><td>Core product<\/td><\/tr><tr><td><strong>Pipeline Candidates<\/strong><\/td><td>Infantile spasms, Duchenne muscular dystrophy, hyperphenylalaninemia<\/td><td>Preclinical\/IND\u2011enabling<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Pipeline Strategy:<\/strong> Diverse global product pipeline targeting significant unmet clinical needs in <strong>CNS disorders and rare pediatric diseases<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-market-opportunity\">Strategic Positioning &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CNS Market:<\/strong> China\u2019s CNS therapeutics market valued at <strong>\u00a5120\u202fbillion<\/strong> (~US$17\u202fbillion) in 2025, growing at <strong>9% CAGR<\/strong> driven by epilepsy, Parkinson\u2019s, and neuro\u2011rare diseases<\/li>\n\n\n\n<li><strong>Rare Disease Opportunity:<\/strong> China\u2019s rare disease market projected to reach <strong>\u00a590\u202fbillion<\/strong> by 2030, supported by improved diagnosis and orphan drug incentives<\/li>\n\n\n\n<li><strong>Platform Differentiation:<\/strong> Proprietary drug delivery platform enables differentiated formulations with potential for improved safety, efficacy, and patient compliance<\/li>\n\n\n\n<li><strong>Integrated Advantage:<\/strong> In\u2011house manufacturing and commercial capabilities reduce reliance on third\u2011party contractors, accelerating time\u2011to\u2011market<\/li>\n\n\n\n<li><strong>Revenue Outlook:<\/strong> Analysts estimate Aucta could achieve <strong>\u00a5500\u2013800\u202fmillion<\/strong> (US$70\u2013110\u202fmillion) in peak sales by 2030 based on lead epilepsy assets and rare disease pipeline<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding IPO timeline, commercial expectations, and revenue projections for Aucta Pharma\u2019s product pipeline. Actual results may differ due to market conditions, regulatory review outcomes, and competitive dynamics in specialty pharma.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012602070_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26012602070_c.\"><\/object><a id=\"wp-block-file--media-c75ef506-8cdd-4dfc-8bd4-c671c4d81b95\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012602070_c.pdf\">sehk26012602070_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012602070_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c75ef506-8cdd-4dfc-8bd4-c671c4d81b95\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Aucta Pharmaceuticals Co., Ltd. made its initial public offering (IPO) filing to the Hong&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55620,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4576,30,72],"class_list":["post-55618","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-aucta-pharmaceuticals","tag-biotech","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Aucta Pharmaceuticals Co., Ltd. made its initial public offering (IPO) filing to the Hong Kong Stock Exchange, positioning to become the next China\u2011based specialty pharma to tap public markets. Unit pricing and offering details remain undisclosed pending regulatory review.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55618\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline\" \/>\n<meta property=\"og:description\" content=\"Shanghai Aucta Pharmaceuticals Co., Ltd. made its initial public offering (IPO) filing to the Hong Kong Stock Exchange, positioning to become the next China\u2011based specialty pharma to tap public markets. Unit pricing and offering details remain undisclosed pending regulatory review.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55618\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-27T10:09:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-27T10:09:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2709.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55618#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55618\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline\",\"datePublished\":\"2026-01-27T10:09:29+00:00\",\"dateModified\":\"2026-01-27T10:09:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55618\"},\"wordCount\":322,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55618#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2709.webp\",\"keywords\":[\"Aucta Pharmaceuticals\",\"Biotech\",\"IPO\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55618#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55618\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55618\",\"name\":\"Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55618#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55618#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2709.webp\",\"datePublished\":\"2026-01-27T10:09:29+00:00\",\"dateModified\":\"2026-01-27T10:09:30+00:00\",\"description\":\"Shanghai Aucta Pharmaceuticals Co., Ltd. made its initial public offering (IPO) filing to the Hong Kong Stock Exchange, positioning to become the next China\u2011based specialty pharma to tap public markets. Unit pricing and offering details remain undisclosed pending regulatory review.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55618#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55618\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55618#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2709.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2709.webp\",\"width\":1080,\"height\":608,\"caption\":\"Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55618#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Aucta Pharmaceuticals Co., Ltd. made its initial public offering (IPO) filing to the Hong Kong Stock Exchange, positioning to become the next China\u2011based specialty pharma to tap public markets. Unit pricing and offering details remain undisclosed pending regulatory review.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55618","og_locale":"en_US","og_type":"article","og_title":"Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline","og_description":"Shanghai Aucta Pharmaceuticals Co., Ltd. made its initial public offering (IPO) filing to the Hong Kong Stock Exchange, positioning to become the next China\u2011based specialty pharma to tap public markets. Unit pricing and offering details remain undisclosed pending regulatory review.","og_url":"https:\/\/flcube.com\/?p=55618","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-27T10:09:29+00:00","article_modified_time":"2026-01-27T10:09:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2709.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55618#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55618"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline","datePublished":"2026-01-27T10:09:29+00:00","dateModified":"2026-01-27T10:09:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55618"},"wordCount":322,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55618#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2709.webp","keywords":["Aucta Pharmaceuticals","Biotech","IPO"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55618#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55618","url":"https:\/\/flcube.com\/?p=55618","name":"Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55618#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55618#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2709.webp","datePublished":"2026-01-27T10:09:29+00:00","dateModified":"2026-01-27T10:09:30+00:00","description":"Shanghai Aucta Pharmaceuticals Co., Ltd. made its initial public offering (IPO) filing to the Hong Kong Stock Exchange, positioning to become the next China\u2011based specialty pharma to tap public markets. Unit pricing and offering details remain undisclosed pending regulatory review.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55618#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55618"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55618#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2709.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2709.webp","width":1080,"height":608,"caption":"Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55618#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2709.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55618"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55618\/revisions"}],"predecessor-version":[{"id":55622,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55618\/revisions\/55622"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55620"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}